NovoSeven® RT controls bleeds quickly in hemophilia A or B with inhibitors

Chase, has congenital hemophilia with inhibitors



 

NovoSeven® RT responds with speed to control bleeds

Infusion time

Bleed resolution

  • Fast to mix with MixPro™
  • Takes only 2 to 5 minutes to infuse
  • Controlled bleeds in as few as 5 hours in a study with a median of 2 dosesa
  • For joint bleeds requiring more than 1 dose, NovoSeven® RT can be used as quickly as every 2 hours, compared with 12 hours for pd-aPCCb

aBased on individual dosage for joint bleeds in people with hemophilia A or B with and without inhibitors.
bpd-aPCC=plasma-derived activated prothrombin complex concentrate.


 



 

Rely on the proven effectiveness of NovoSeven® RT


86% effective in controlling muscle bleeds in a clinical study


91% effective in controlling joint bleeds in a clinical study

Also proven effective in adept™2

93%

One of the largest clinical trials of people with hemophilia with inhibitors


Joint, target joint, skin and mucous membrane, muscle, and other bleeding episodes

(n=227 bleeding episodes)


 



 

The safety of NovoSeven® RT is well studied


 


 
 
  • Works at the site of injury
  • Less than 1% rate of thrombotic adverse events (blood clots)c in clinical trials


c
In people with hemophilia A or B with inhibitors.


 


 



 


 

Use in surgery

NovoSeven® RT prevents bleeds during and after surgery in children and adults with congenital hemophilia A or B with inhibitors. Talk with your doctor for more information.


 


Selected Important Safety Information

WARNING: BLOOD CLOTS

  • Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported.
  • Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function.
  • Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT.

Indications and Usage

NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) is used for:

  • Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and people with Glanzmann's thrombasthenia who have a decreased or absent response to platelet transfusions
  • Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults with acquired hemophilia

Important Safety Information

WARNING: BLOOD CLOTS

  • Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported.
  • Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function.
  • Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT.

Warnings and Precautions

  • NovoSeven® RT should be used with caution if you have an increased risk for blood clots, such as with disseminated intravascular coagulation (DIC), clogged arteries, crush injury, septicemia (an infection in the blood), uncontrolled bleeding after giving birth, history of heart disease, liver disease, limited movement following surgery, in elderly people, in newborns, or if you are taking aPCCs/PCCs (activated or nonactivated prothrombin complex concentrates) with NovoSeven® RT.
  • Allergic reactions, including serious whole body allergic reactions, have been reported with NovoSeven® RT. Tell your healthcare provider if you are allergic to NovoSeven® RT, any of its ingredients, or mice, hamsters, or cows. If you think you are having an allergic reaction, call your healthcare provider right away. Some signs of allergic reaction may include shortness of breath, rash, itching, redness of the skin, and fainting/dizziness.
  • People with Factor VII deficiency should be monitored by their healthcare provider for antibodies, which can cause NovoSeven® RT to stop working properly.

Side Effects

  • The most common and serious side effects are blood clots.
  • Tell your healthcare provider about any side effects that bother you or do not go away.

Use with Other Drugs

  • Blood clots may occur if NovoSeven® RT is given with Coagulation Factor XIII (13).

Please click here for Prescribing Information and Instructions for Use.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

NovoSeven® RT is a prescription medication. Novo Nordisk provides patient assistance for those who qualify. Please call 1-877-NOVO-777 (1-877-668-6777) to learn more about Novo Nordisk assistance programs.